EQUALY sa.

EQUALY sa. is a biotechnology company focused on developing innovative approaches to combat cancer through immuno-oncology. EQUALY sa. leverages the role of a newly discovered type of Natural Killer T (NKT) cells to create groundbreaking immunological strategies aimed at eliminating tumor cells. The company is dedicated to pioneering therapies that promise to revolutionize cancer treatment by providing safer, more effective, and more affordable alternatives to current options.

Based in Bruxelles, EQUALY sa. operates with a commitment to advancing healthcare through cutting-edge research and development. EQUALY sa. also develops non-immunogenic versions of existing Enzyme Replacement Therapies against metabolic orphan diseases, further expanding its impact on patient care. The company's primary address is Bruxelles, 1200, BE, with additional operations in Louvain-la-Neuve, BE.

EQUALY sa. is positioned to make significant contributions to the field of biotechnology, driven by its innovative approach and dedication to improving patient outcomes. We invite the manager of EQUALY sa. to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.